Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
about
Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial originModified epidermal growth factor receptor (EGFR)-bearing liposomes (MRBLs) are sensitive to EGF in solutionNeutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptorOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative meUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II studySkin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts.The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.Randomized double-blind trial of prophylactic topical Evozac(®) Calming Skin Spray for gefitinib-associated acne-like eruption.Biological agents in gastrointestinal cancers: adverse effects and their management.Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerDoes chemistry have a future in therapeutic innovations?The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin LymphomaRisk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials.Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment.Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Alopecia in patients treated with molecularly targeted anticancer therapies.Toxicity as a result of immunostimulation by biologics.Current role of antibody therapy in patients with metastatic colorectal cancer.A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.Evaluation of hypertension as a marker of bevacizumab efficacyPredictive and prognostic markers in colorectal cancer.Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies.Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer.Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886).Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.Trichomegaly and other external eye side effects associated with epidermal growth factor.The management of EGFR inhibitor adverse events: a case series and treatment paradigm.Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.Targeting the epidermal growth factor receptor in solid tumor malignancies.Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.
P2860
Q24645217-FFEAE465-58C4-4E5D-BE18-FD73AD55063FQ28476290-D3CDDF8F-230C-4820-AF3C-0F0905119CAFQ28728031-A75D7FEA-5E33-4D93-868D-B5323D7F65E6Q30376023-D63B307D-3535-4151-8945-E4C513D38969Q33408049-9B6B0556-A6A8-41BE-8FDC-63B55524B7B7Q33779303-1952D611-52CF-4A71-96D3-3F935BE230BEQ33825878-930AEDAB-E0D8-43B9-8395-37E22C8AE4B5Q33865354-84B88F6B-3492-4404-96B8-8A71B70601AEQ33895537-2BA42D16-AEB1-4533-8872-0CE4F638ABD2Q33895581-91CF5DCC-3D09-420C-8391-E2049C65D995Q33983656-1378E0BA-C146-4E1C-BF02-218DE1291246Q34331745-5DB49D0B-B1D1-41A6-B5C1-34AF3A9EDAE5Q34343043-E435F4D5-5A8F-49BC-8CAA-AB31A93A7C3FQ34534572-114595CA-4D8E-4008-BEC4-D3DE8613391EQ35211367-7C165FB9-E30C-4425-8ACC-1AF63F82EF20Q35584416-0AEC21F7-308F-4B35-A023-290B7933335CQ35623078-C60BEC76-7FBB-4476-A9DE-571225C3BD31Q35653271-6F7D7082-E18D-408F-B7A8-CA461796A799Q35913241-5AF4F6AF-948E-4FEF-9CD7-788CFCC6A063Q36012730-F6E13C52-FB2F-4B70-B10E-2C2824E56C8CQ36316632-7B22621A-47D0-4167-8039-A40EEE3CD24CQ36788414-DE9F93C2-FD10-47CF-B6BD-F842A71B15A6Q36832121-12B22384-2E8B-4D28-AA2A-4AD78BF2E28CQ36951089-8571562B-C5FB-4824-BA89-C0AC51A2860BQ36991546-6A5D27DF-7FDA-4B78-AE3E-5289424CFE97Q37073444-7DCB6406-6636-475F-87B1-608EB8CA6822Q37235724-A96D9EF9-8BB5-4646-8DEA-EA437A6FFBCBQ37359711-2A7ABD30-C45B-4A71-8F8C-DAA63FEA0099Q37385584-EB73E8AC-7C21-4A25-A213-E0165378F399Q37390753-722B1FC0-11BD-4FD9-BDE9-D48049DEA4FAQ37442683-7C4132A2-8E4D-45FF-8993-7FE033D5FD08Q37558534-136DD4A4-F750-4B01-BD8B-5D24ABAF3F0EQ37645195-92EE8922-EA4E-4FA0-8A95-ACC4FA0C4ABCQ37803366-08233677-C006-43D1-B02A-2C9BF4DFDBD9Q37899883-2DB5BF3E-2511-4FB8-888F-BD744B839B64Q37961813-12AFDD8E-8263-4EE0-8F96-FF62E5F54C0BQ37976416-820B8529-1697-4E84-8C69-2BBD069494FDQ37987802-02445896-5463-4B1C-BD39-3A4DAF3512B6Q37990044-66E2EDE6-3480-42DA-86E2-413522F7EE68Q38038034-614C9D4B-C4F2-4B70-8007-D036661E0224
P2860
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Dermatologic side effects asso ...... th factor receptor inhibitors.
@ast
Dermatologic side effects asso ...... th factor receptor inhibitors.
@en
type
label
Dermatologic side effects asso ...... th factor receptor inhibitors.
@ast
Dermatologic side effects asso ...... th factor receptor inhibitors.
@en
prefLabel
Dermatologic side effects asso ...... th factor receptor inhibitors.
@ast
Dermatologic side effects asso ...... th factor receptor inhibitors.
@en
P2093
P1476
Dermatologic side effects asso ...... th factor receptor inhibitors.
@en
P2093
Allan C Halpern
Anna Liza C Agero
Cristiane Benvenuto-Andrade
Klaus J Busam
Patricia Myskowski
Stephen W Dusza
P304
P356
10.1016/J.JAAD.2005.10.010
P407
P577
2006-10-01T00:00:00Z